Group 1 - The core viewpoint of the article highlights that Rongchang Biologics (09995) has seen a stock price increase of over 5%, currently trading at 90 HKD with a transaction volume of 1.52 billion HKD, following the acceptance of its RC288 injection application by NMPA [1] - RC288, a PSMA/B7H3ADC developed by Rongchang Biologics, has demonstrated excellent anti-tumor activity and safety in preclinical studies [1] - According to Guotai Junan Securities, Rongchang Biologics is expected to enter a new growth phase starting in 2026, primarily benefiting from the launch of new indications for RC18, RC48, and RC28, which will be included in medical insurance [1] Group 2 - The overseas indications for RC48 and RC18 are projected to be launched and sold starting in 2027, contributing to sales revenue for the company [1] - From 2025, the company is anticipated to achieve multiple asset licensing agreements, with upfront payments and milestones expected to be confirmed in the coming years, enhancing the financial statements [1] - The newly entered global FIC pipeline, including CDCP1ADC RC278 and B7H3/PSMA ADC RC288, possesses potential global competitiveness and may lead to licensing opportunities [1]

Core Viewpoint - Rongchang Biopharma (09995) has seen its stock price increase by over 5%, currently trading at 90 HKD, following the acceptance of its RC288 injection application by NMPA, indicating strong market interest in its innovative drug pipeline [1] Group 1: Product Development - The RC288 injection, developed by Rongchang Biopharma, is a PSMA/B7H3 ADC that has demonstrated excellent anti-tumor activity and safety in preclinical studies [1] - The company is expected to enter a new growth phase starting in 2026, primarily driven by the launch of new indications for RC18, RC48, and RC28, which will also be included in medical insurance [1] Group 2: Future Revenue Streams - Sales from overseas indications for RC48 and RC18 are projected to begin in 2027, contributing to revenue through sales sharing agreements [1] - Starting in 2025, the company anticipates multiple asset licensing agreements, with upfront payments and milestones expected to enhance financial statements in the coming years [1] Group 3: Competitive Positioning - The newly entered global FIC pipeline, including CDCP1 ADC RC278 and B7H3/PSMA ADC RC288, holds potential global competitiveness and may lead to external licensing opportunities [1]

Coal Mining Research - The report discusses the historical impact of geopolitical conflicts on coal prices, suggesting that these conflicts may stabilize seasonal price declines and elevate average prices. The ongoing geopolitical tensions, particularly involving the US, Israel, and Iran, have led to higher oil and natural gas prices, which are expected to influence energy prices upward. International coal prices have risen by 20% in response to the surge in natural gas prices, leading to increased expectations for coal demand amid high energy prices [3][4] - Domestic coal supply remains stable, but a reduction in imports due to rising international coal prices may elevate domestic seasonal coal price bottoms, making significant price drops unlikely. The peak supply-demand pressure is expected to end around March-April, with a seasonal increase in electricity coal demand starting in May [3][4] Construction Engineering Research - China Power Construction Corporation (中国电建) is highlighted for its leadership in global clean energy construction, with a significant market share in wind, solar, and hydropower projects. The company has completed over 80% of river planning and more than 65% of large and medium-sized hydropower station construction in China, and it leads over 50% of the global market for large and medium-sized hydropower projects [6][7] - The report notes that the integration of computing and electricity has been included in government reports, which is expected to benefit companies involved in integrated computing and electricity operations. The company has signed contracts worth 210.06 billion yuan for digital transformation projects, including data centers and computing centers [5][7] Biopharmaceutical Research - Rongchang Biopharmaceutical (荣昌生物) is projected to enter a new growth phase starting in 2026, driven by the launch of new indications for its products RC18, RC48, and RC28, which are expected to enter medical insurance coverage. The company anticipates revenue of 32.51 billion yuan in 2025, increasing to 78.32 billion yuan in 2026, and 62.79 billion yuan in 2027 [8][31] - The report emphasizes the potential of RC148, a dual antibody product, which is expected to gain market share through partnerships and new indications, enhancing the company's competitive position in the global oncology market [9][32]

Investment Rating - The report assigns an "Accumulate" rating to Rongchang Biopharma with a target price of 143.89 RMB [4]. Core Insights - The report predicts that Rongchang Biopharma will enter a new growth phase starting in 2026, driven by the launch of new indications for RC18, RC48, and RC28, which are expected to enter the medical insurance coverage [11][15]. - The company is expected to achieve revenue of 32.51 billion RMB in 2025, 78.32 billion RMB in 2026, and 62.79 billion RMB in 2027, with a significant increase in net profit anticipated in 2026 [3][11]. Financial Summary - Total revenue is projected to grow from 1,083 million RMB in 2023 to 7,832 million RMB in 2026, reflecting a growth rate of 140.9% [3]. - Net profit (attributable to the parent company) is expected to turn positive in 2025 with a forecast of 644 million RMB, and further increase to 5,031 million RMB in 2026 [3]. - Earnings per share (EPS) is projected to rise from -2.68 RMB in 2023 to 8.91 RMB in 2026 [3]. Revenue Growth Drivers - The anticipated growth is attributed to the approval and market entry of new indications for RC48 and RC18, as well as the expected launch of RC28 [15][21]. - RC48 is set to be approved for first-line treatment of UC and HER2 low-expressing breast cancer, which will significantly expand its market potential [16][21]. - RC18 is expected to see increased volume as it enters medical insurance coverage for multiple indications, including MG and IgAN [21][25]. Strategic Partnerships - The company has entered into several strategic partnerships, including the licensing of RC148 to AbbVie, which is expected to enhance its global competitive position in oncology [34][36]. - The partnership with Santen Pharmaceutical for RC28 is also expected to maximize its market potential in the ophthalmic sector [30]. Clinical Development Pipeline - The report highlights the ongoing clinical trials for RC148, which show promising efficacy in treating various cancers, including NSCLC [36][38]. - RC18 is advancing in global clinical trials, with significant potential for treating MG and other autoimmune diseases [25][26]. Market Positioning - Rongchang Biopharma is positioned to leverage its innovative drug pipeline and strategic partnerships to capture significant market share in the oncology and autoimmune sectors [11][34].

2026 年展望：加入全球肿瘤一线竞争 荣昌生物(688331) | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 余克清(分析师) | 010-56760093 | yukeqing@gtht.com | S0880525120002 | | 廖博闻(研究助理) | 021-23187268 | liaobowen@gtht.com | S0880125042239 | 本报告导读： 本篇报告是我们对荣昌生物 2025 年的回顾梳理，以及 2026 年的展望 | [Table_Invest] | 首次覆盖 | | --- | --- | | 评级 | 增持 | | 目标价格 | 143.89 | [当前价格： Table_CurPrice] 118.90 [Table_Market] 交易数据 | 52 周内股价区间(元) | 29.80-118.90 | | --- | --- | | 总市值( ...

Investment Rating - The industry investment rating is "Overweight" [6] Core Insights - Yum China reported Q3 2025 revenue of $3.2 billion, a year-on-year increase of 4%, and core operating profit of $399 million, up 8%, aligning with expectations [1][4] - The net new store openings for KFC and Pizza Hut reached a record high in Q3, with a total of 536 new stores, bringing the total to 17,514 [2][4] - Same-store sales for KFC increased by 2% year-on-year, while Pizza Hut saw a 1% increase, marking the 12th consecutive quarter of positive same-store sales growth [5] Summary by Sections Overseas Catering - Yum China achieved Q3 2025 revenue of $3.2 billion, a 4% increase year-on-year, and core operating profit of $399 million, an 8% increase, meeting expectations [1][4] - KFC and Pizza Hut net new store openings reached a record high in Q3, with 536 new stores added, totaling 17,514 stores [2][4] - KFC's same-store sales increased by 2% year-on-year, with transaction volume up 3% and average ticket price down 1% to 38 yuan [5] Overseas Pharmaceuticals - Rongchang Biologics reported a 42.3% year-on-year revenue increase in the first three quarters of 2025, reaching 1.72 billion yuan, with a net loss of 551 million yuan, narrowing by 48.6% [8] - In Q3, revenue grew by 33.1% year-on-year and 8.7% quarter-on-quarter, reaching 622 million yuan, with a net loss of 101 million yuan, narrowing by 65.2% year-on-year [8] - The company’s R&D expenses decreased by 22.8% year-on-year to 891 million yuan in the first three quarters [8] Overseas Education - The education sector's growth rate has bottomed out, with New Oriental's revenue growth accelerating due to its strong reputation [3] - The education index fell by 6.0% in the week of October 31 to November 6, underperforming the Hang Seng Index by 6.1 percentage points [15] - New Oriental's GMV on Douyin was approximately 170 million yuan for the week, with a daily average of 24.2 million yuan, reflecting a 2.7% week-on-week decline [16]

Investment Rating - The report maintains an "Overweight" rating for the overseas consumer services sector, indicating a positive outlook for the industry [1]. Core Insights - Yum China reported a revenue of $3.2 billion for Q3 2025, a year-on-year increase of 4%, with core operating profit rising by 8% to $399 million, aligning with expectations [1][4]. - The company achieved a record net store opening of 536 locations in Q3, bringing the total to 17,514 stores, with KFC and Pizza Hut expanding into over 310 and 170 new cities respectively [2][4]. - Same-store sales for KFC grew by 2% year-on-year, driven by a 3% increase in transaction volume, while Pizza Hut's same-store sales increased by 1% with a significant 17% rise in transaction volume [5]. Summary by Sections Overseas Consumer Services - Yum China accelerated its store opening pace in Q3 2025, achieving a total of 536 new stores, with KFC at 12,640 and Pizza Hut at 4,022 [2][4]. - The company has entered over 310 new cities for KFC and 170 for Pizza Hut in the past 12 months, with a total of approximately 2,500 and 1,000 cities served respectively [2][4]. - New store formats, such as KFC Coffee and KPRO, are expanding consumer engagement and market presence [2][4]. Overseas Pharmaceuticals - Rongchang Bio reported a 42.3% year-on-year revenue growth for the first three quarters of 2025, reaching 1.72 billion yuan, with a net loss of 551 million yuan, narrowing by 48.6% [9]. - The third quarter saw a revenue increase of 33.1% year-on-year, amounting to 622 million yuan, with a net loss of 101 million yuan, a significant reduction of 65.2% year-on-year [9]. - The company’s R&D expenses decreased by 22.8% year-on-year to 891 million yuan, while sales expenses increased by 32.1% to 823 million yuan, with a sales expense ratio decline of 3.7 percentage points to 47.8% [9]. Overseas Education - The education sector's growth has stabilized, with New Oriental experiencing a revenue acceleration driven by its strong brand reputation [16]. - The education index fell by 6.0% in the week of October 31 to November 6, underperforming the Hang Seng Index by 6.1 percentage points [16]. - New Oriental's GMV on Douyin was approximately 170 million yuan, with a daily average of 24.2 million yuan, reflecting a 2.7% week-on-week decline [17].

Core Insights - The report highlights a significant divergence in performance across various sectors within the public REITs market for Q3 2025, with utility, rental housing, and consumer sectors showing robust growth, while logistics and transportation sectors are underperforming [4][14] - The overall market experienced a V-shaped rebound in October, driven by the central bank's resumption of public bond trading, leading to a notable increase in trading volume and a recovery in valuations [5][14] Sector Performance Summary - **Utility Sector**: Demonstrated exceptional performance with EBITDA growth exceeding 10% year-on-year, indicating strong demand and operational efficiency [4][14] - **Rental Housing and Consumer Sectors**: Both sectors showed steady performance with positive year-on-year growth in revenue, EBITDA, and distributable amounts, reflecting resilience in consumer spending [4][14] - **Logistics and Transportation Sectors**: These sectors faced significant challenges, with over 80% of companies in the industrial park sector reporting declines in performance, and only a few companies in the transportation sector achieving growth [4][14] - **Energy Sector**: Overall performance declined, with most projects reporting significant year-on-year decreases in revenue and EBITDA, except for a few standout companies [4][14] Market Trends - **Dividend Yields**: The latest dividend yield for property REITs rose to 4.06%, with a spread of 2.27% over the 10-year government bond yield, indicating a favorable investment environment for income-seeking investors [5][14] - **Valuation Recovery**: Valuations for property and operating rights REITs have rebounded to the 66% and 72% percentiles, respectively, suggesting a recovery in investor confidence [5][14] - **New REITs Performance**: A significant disparity in the performance of newly established REITs was noted, with only 14% of those established in 2025 meeting their expected distributable amounts [4][14] Company-Specific Insights - **Ding Tai Gao Ke (301377)**: Reported a revenue of 1.457 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 29.13%, with a notable profit increase of 63.94% [13] - **Rongchang Bio (09995.HK)**: Achieved a revenue of 1.72 billion yuan in the first three quarters of 2025, a 42.3% increase year-on-year, with a significant reduction in net losses [15][16] - **Zhong Tung Gao Xin (000657)**: Announced plans for capacity expansion in response to high demand for PCB drill bits, with a projected increase in monthly production capacity [20][21]

Group 1: Market Overview - The Q3 2025 performance of public REITs shows significant differentiation, with utility sectors performing best, while warehousing, logistics, and transportation sectors are underperforming [2][3] - The market experienced a rebound in October, with leading assets showing significant gains and a widening interest margin, with valuations recovering to above the 60th percentile [3][10] - The latest dividend yield for property REITs has risen to 4.06%, with a spread of 2.27% over the 10Y government bond yield, indicating improved performance in utility and consumer sectors [3][10] Group 2: Sector Performance - Utility, affordable rental housing, and consumer sectors have shown positive year-on-year growth in revenue, EBITDA, and distributable amounts, with the utility sector's EBITDA growing over 10% [2][3][13] - The industrial park sector has seen the most significant decline, with over 80% of individual securities experiencing performance drops, and EBITDA and distributable amounts declining by over 10% [2][3][13] - The transportation sector has limited high-performing securities, with only Anhui Expressway and Hebei Expressway showing comprehensive growth [2][3][13] Group 3: Company-Specific Insights - Ding Tai Gao Ke reported a revenue of 1.457 billion yuan for Q1-Q3 2025, a year-on-year increase of 29.13%, with Q3 revenue reaching 553 million yuan, up 32.94% year-on-year [12] - The company has improved its gross margin to 40.62% for Q1-Q3 2025, benefiting from product structure optimization and price increases [15] - The PCB industry is experiencing strong demand, with the company planning to accelerate capacity expansion to meet the growing needs [15][19]

Core Viewpoint - Morgan Stanley has downgraded the product revenue forecasts for Rongchang Biologics (09995, 688331.SH) for 2025 and 2026, reflecting the latest performance, while raising the forecast for licensing revenue [1] Group 1: Financial Performance - The third-quarter performance of Rongchang Biologics was mixed, with product revenue lower than the bank's expectations, but profit margins and operating expenses were better controlled than anticipated, indicating ongoing cost optimization by the company [1] - The bank expects the net loss for 2025 and 2026 to narrow due to improved profit margins and reduced operating expenses [1] Group 2: Target Price and Ratings - The target price for H-shares has been raised from HKD 73 to HKD 77, with the rating upgraded to neutral; the target price for A-shares has been increased from RMB 86 to RMB 92, maintaining a "neutral" rating [1] Group 3: Cost Management - Following the signing of the RC18 licensing agreement with VorBio in June, the company's R&D expenses decreased by 30% year-on-year and 24% quarter-on-quarter; administrative expenses also fell by 23%, continuing the positive trend from previous quarters [1]